Gain Therapeutics Stock Forum

$Gain Therapeutics(GANX.US)$ Gain Therapeutics Inc - Topline Data to Be Presented Mid-August! No discontinuations or adverse events!

$Gain Therapeutics(GANX.US)$
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
Gain Therapeutics has presented data at the Federation of European Neuroscience Societies (FENS) Forum 2024 showing that their lead therapeutic candidate, GT-02287, has significantly improved cognitive function and activities of daily living in a preclinic...

$Gain Therapeutics(GANX.US)$
Gain Therapeutics Announces Pricing of $11.0 Million Public Offering

$Gain Therapeutics(GANX.US)$
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
Gain Therapeutics has announced that its late-breaking abstract on GT-02287, a clinical-stage GCase enhancer, has been accepted for presentation at the FENS Forum 2024 in Vienna. New data reveals improvements in cognitive performance in a preclinical model of GBA1 Parkinson’s disease. The presentation is sched...

$Gain Therapeutics(GANX.US)$ Gain Therapeutics Announces Positive Results From the Single Ascending Dose (Sad) Part of the Phase 1 Clinical Trial of GT-02287, a Novel Gcase-Targeting Small Molecule Therapy for Gba1 Parkinson’s Disease

$Gain Therapeutics(GANX.US)$
NEWS
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Positive results from the SAD part of the Phase 1 Clinical Trial of GT-02287.
GT-02287 was well tolerated with no serious adverse events.
Achieved appropriate plasma exposure levels after oral administration.
GT-02287 has the potential to slow or stop Parkinso...

$Gain Therapeutics(GANX.US)$ EXCLUSIVE: Gain Therapeutics Tells Benzinga 'Data Support the Ability of GT-02287 to Prevent Several Steps in the Disease Cascade Resulting From GCase Misfolding and Dysfunction'

$Gain Therapeutics(GANX.US)$ Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease
7 MINUTES AGO, 2:00 PM EST
VIA GLOBENEWSWIRE

$Gain Therapeutics(GANX.US)$Moomoo 24/7· 1 min ago
Gain Therapeutics Announces Preclinical Data Demonstrating GT-02287 Restored Motor Function In Mouse Models Of Parkinson's Disease